The sponsorship was transferred to Quality Regulatory Clinical Ireland Limited, Ireland, in September 2019.
On 19 November 2014, orphan designation (EU/3/14/1357) was granted by the European Commission to Numedicus Ltd, United Kingdom, for imatinib for the treatment of acute respiratory distress syndrome.
The sponsorship was transferred to Exvastat - United Kingdom in March 2017.
|Disease / condition||
Treatment of acute respiratory distress syndrome (ARDS)
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.